Latest news

Janux's T-cell therapy misses the mark

Janux's T-cell therapy misses the mark

Joachim Eeckhout
Belite Bio's Phase 3 success in Stargardt

Belite Bio's Phase 3 success in Stargardt

Joachim Eeckhout
Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Otsuka’s first FDA-approved anti-APRIL therapy & Valneva's site closure

Joachim Eeckhout
Daily Snap - 26. November 2025

Daily Snap - 26. November 2025

Joachim Eeckhout
Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Gilead invests $414M into TREX1 cancer drug from Sprint Bioscience

Eduardo Longoria
Daily Snap - 25. November 2025

Daily Snap - 25. November 2025

Joachim Eeckhout
Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Novo Nordisk’s Alzheimer’s trials fail, casting doubt on GLP-1 drugs for neurodegeneration

Eduardo Longoria
Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Versant launches Dayra with $50M Biogen deal to chase oral macrocyclic peptide drugs

Eduardo Longoria
Daily Snap - 24. November 2025

Daily Snap - 24. November 2025

Joachim Eeckhout
Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Contineum’s multiple sclerosis drug fails phase 2 test, raising doubts on its potential

Eduardo Longoria
Daily Snap - 21. November 2025

Daily Snap - 21. November 2025

Joachim Eeckhout
Aspen secures $115M to advance its Parkinson’s research and a pivotal trial

Aspen secures $115M to advance its Parkinson’s research and a pivotal trial

Eduardo Longoria
FirstBack
345678910
Next Last